NCT02244827View on ClinicalTrials.gov

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

June 30, 2015

Conditions

Hepatic Impairment

Interventions

DRUG

WCK 2349

levonadifloxacin (active drug) and the sulfate metabolite

Trial Locations (1)

33136

University of Miami,Division of Clinical Pharmacology, Miami

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Wockhardt

INDUSTRY

NCT02244827 - Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment | Biotech Hunter | Biotech Hunter